Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
April 12, 2022

HeatNMof is a heating-triggered drug release from nanometric metal-organic framework composites

The Initial Training Network HeatNMof aims to develop high quality training opportunities for 12 early-stage-researchers (ESRs) in the area of materials science, advanced characterization and biomedicine.


HeatNMof is training the next generation of materials scientists in nanomedicine to exploit heat-triggered release for delivery of anti-tumour drugs. The network is focusing on one of the most promising classes of nanocomposite carriers, inorganic nanoparticles (iNPs) associated to nanoscaled metal organic frameworks (nanoMOFs).


The successful development of this project, involving seven academic, three industrial partners, six partner organisations (5 universities and 1 company), will contribute to the improvement of the highly societal relevant cancer therapy..


Partners: Fundación IMDEA Energía (Coordinator), Universidad de Santiago de Compostela; Centre National de la Recherche Scientifique; Universiteit Antwerpen; Immaterial Labs Ltd; Institut National des Sciences Appliquees de Toulouse; Universitaet Hamburg; Fondazione Istituto Italiano di Tecnologia.; Nanoscale Biomagnetics SL; Isern Patentes Y Marcas M SL.


- Partner Organisations: Universidad Rey Juan Carlos; Universidad de Zaragoza, University of Cambridge; Universite de Nantes; Universita Degli Studi di Genova; Pharmidex.


Funding Institution/Program: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement Nº 860942.


Call: H2020-MSCA-ITN-2019 (ETN)


https://www.energy.imdea.org/research/projects/heatnmof

May 20, 2026
We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.
May 19, 2026
Pharmidex is pleased to announce that Janette Dalay Robertson , Business Development Manager, will be attending the Milner Seminar May 2026 hosted by the Milner Therapeutics Institute at the Jeffrey Cheah Biomedical Centre , Cambridge, on 19 May 2026 from 4:00–5:00pm. The seminar will bring together experts from academia and industry to discuss innovation and collaboration in drug discovery and translational science. Pharmidex will also be exhibiting at the event. Janette will be near the café in the Jeffrey Cheah Biomedical Centre from 11am tomorrow, so if you would like to discuss drug discovery, preclinical development, bioanalysis, or potential collaborations, please feel free to stop by for a chat before the seminar begins. Looking forward to connecting with researchers, biotech innovators, and industry partners throughout the day!
May 18, 2026
We’re pleased to highlight Gaurang Patel and his extensive expertise in clinical and bioanalytical research. With more than 19 years of experience spanning analytical development, method validation, and regulatory-compliant environments, Gaurang brings deep scientific knowledge and operational leadership to every programme. His commitment to robust analytical methods, laboratory excellence, quality, and compliance continues to support the delivery of reliable, efficient, and audit-ready outcomes across complex research projects. At Pharmidex , we value the experience and dedication that help drive scientific progress and trusted partnerships.
More Posts